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The XPD helicase (Rad3 in Saccharomyces cerevi-
siae) is a component of transcription factor IIH
(TFIIH), which functions in transcription initiation
and Nucleotide Excision Repair in eukaryotes, cata-
lyzing DNA duplex opening localized to the transcrip-
tion start site or site of DNA damage, respectively.
XPD has a 50 to 30 polarity and the helicase activity
is dependent on an iron-sulfur cluster binding do-
main, a feature that is conserved in related helicases
such as FancJ. The xpd gene is the target of mutation
in patients with xeroderma pigmentosum, trichothio-
dystrophy, and Cockayne’s syndrome, character-
ized by a wide spectrum of symptoms ranging from
cancer susceptibility to neurological and develop-
mental defects. The 2.25 A˚ crystal structure of XPD
from the crenarchaeon Sulfolobus tokodaii, pre-
sented here together with detailed biochemical anal-
yses, allows a molecular understanding of the struc-
tural basis for helicase activity and explains the
phenotypes of xpd mutations in humans.
INTRODUCTION
XPD (Rad3 in S. cerevisiae) is a superfamily 2 DNA helicase with
a 50-30 polarity. In eukaryotes, XPD is a component of the tran-
scription factor IIH (TFIIH), along with the helicase XPB (Rad25)
and eight other protein subunits. TFIIH is essential for RNA poly-
merase (RNAP) II-mediated transcription initiation and for the
Nucleotide Excision Repair (NER) pathway. In both situations,
the role of TFIIH is to open up the DNA duplex, around the
promoter or site of DNA damage, allowing access for RNAP or
NER factors in the respective pathways. XPD is the structural
bridge linking the core TFIIH subunits required for NER to the
Cdk-activating kinase (CAK) complex (reviewed in Chen and
Suter, 2003). The helicase activity of XPD is not required for tran-
scription initiation, as point mutations that knock out this function
while preserving the protein structure result in transcription-
competent TFIIH (Winkler et al., 2000). In contrast, mutations
that reduce the helicase activity of XPD cause defects in the
NER pathway. Mutations of human XPD give rise to three relateddiseases: xeroderma pigmentosum (XP), trichothiodystrophy
(TTD), and combined XP with Cockayne’s syndrome (XP/CS)
(Lehmann, 2001). These have a surprisingly wide spectrum of
symptoms, ranging from severe UV sensitivity and a 1000-fold
increased propensity to cancer for XP, through to brittle hair,
transcriptional and developmental defects for TTD. This reflects
the dual role of TFIIH in transcription and repair. Mouse models
for XP/CS and TTD syndromes have highlighted the importance
of segmental progeria, or premature aging, that is thought to be
a consequence of accumulating DNA damage leading to tran-
scriptional defects and apoptosis (Andressoo et al., 2006;
de Boer et al., 2002).
Most archaea encode clear homologs of both the XPD and
XPB helicases (Kelman and White, 2005), but no other subunits
of TFIIH. We have shown previously that archaeal XPD functions
independently as a 50-30 DNA helicase, and that the helicase
activity is dependent on a small iron-sulfur (FeS) binding domain
near the N terminus (Rudolf et al., 2006). This cluster is liganded
by four cysteine residues, three of which are absolutely
conserved in all archaeal and eukaryotic XPD proteins. Mutation
of any of the three conserved cysteines results in disruption of
the FeS cluster and a loss of helicase activity, while the fourth
is not essential (Rudolf et al., 2006). The importance of the FeS
cluster was also demonstrated in S. cerevisiae, where disruption
of the cluster gave rise to a strong UV-sensitive phenotype
in vivo. The human XPD mutation R112H, which inactivates
the helicase activity and gives rise to TTD, probably exerts its
effect by disrupting the FeS cluster (Rudolf et al., 2006).
XPD is the founding member of a family of DNA helicases in
eukaryotes, which includes the FancJ (also known as Bach1,
Brip1), Chl1, and Tel helicases. These helicases are involved in
a variety of DNA repair and recombination pathways in humans,
and all have the conserved cysteine residues diagnostic for
the FeS cluster. Some mutations of FancJ that cause Fanconi
anemia map close to the FeS domain, suggesting that the FeS
cluster is also essential for this enzyme (Pugh et al., 2008; Rudolf
et al., 2006).
The role of the FeS cluster in XPD and related helicases has not
been defined. The observation that the FeS domain is conserved
in a family of helicases with different functions suggests that it is
not specialized for the detection of DNA damage, but rather that
it plays a generic role for these helicases. Although FeS cluster-
containing proteins are often involved in redox reactions, exam-
ples of FeS clusters in a variety of proteins including DNACell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc. 801
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primase (Klinge et al., 2007), RNA polymerase (Hirata et al., 2008)
and DNA glycosylases (Hinks et al., 2002; Kuo et al., 1992)
suggest that FeS clusters can have a purely structural role, anal-
ogous to other metal binding domains. SF1 and SF2 helicases
have two conserved motor domains with a RecA fold, which
couple ATP hydrolysis to translocation along DNA or RNA
strands (reviewed in Singleton and Wigley, 2002). In addition,
they frequently have accessory domains specific for nucleic
acid or protein interactions. XPD mutants with a disrupted FeS
domain still bind to ssDNA and have DNA-dependent ATPase
activity, suggesting that the function of the domain may be to
physically separate the strands of the DNA duplex (Pugh et al.,
2008; Rudolf et al., 2006). There are several examples of acces-
sory domains organized as inserts to the helicase motor domains
that are required for the physical separation of duplex DNA—for
example the beta-hairpin domains of the bacterial DNA repair
helicase UvrB (Theis et al., 1999) and the archaeal SF2 helicase
Hel308 (Buttner et al., 2007).
We now present the X-ray structure of XPD from the archaeon
Sulfolobus tokodaii, to the best of our knowledge, the first re-
ported structure of an SF2 50 to 30 helicase. The XPD structure
allows a molecular interpretation of a number of naturally occur-
ring human mutations that lead to severe human diseases.
RESULTS
Overview of the Structure of XPD
Archaeal and eukaryal XPD proteins share 25% sequence iden-
tity, which includes the seven conserved canonical motifs iden-
tified in the SF2 helicase family (motifs I, Ia, II–VI) (Gorbalenya
and Koonin, 1993) (Figure 1A, Figure S1 available online).
The structure of XPD from the crenarchaeon S. tokodaii was
solved at 2.25 A˚ resolution, and crystallographic statistics are
given in Table 1. There are three major domains (Figure 1B).
The two canonical motor domains (1 and 2) that are present in
all SF1 and SF2 helicases are a good structural match for those
in other helicases, matching with a 2.8 A˚ rmsd over 201 common
Ca positions in the NS3 helicase, for example (Figure S2). The
two motor domains have a central interface in which ATP is
bound and hydrolyzed. In our apo-structure, a phosphate ion is
bound at the predicted catalytic site. The motion of the two mo-
tor domains relative to one other during ATP binding and hydro-
lysis drives DNA translocation. The canonical motifs I, II, III, V,and VI are known from other helicases to be involved in ATP
binding (reviewed in Singleton et al., 2007) and are present in
equivalent positions in XPD, although motif V is unstructured in
our apo-structure (Figure 1B). Motifs Ia, IV, and V are known to
interact with the nucleic acid substrate in other helicases, and
map to the upper surface of motor domains 1 and 2 (Figure 1B).
Additionally, we identify conserved sequence motifs Ib (YxY), Va
(GLPY), and VII (DxRY) in XPD family members that are posi-
tioned to interact with the ssDNA substrate.
A third domain, which we term the Arch domain (residues 194–
303), has a mixed a b topology with a four-stranded antiparallel
Table 1. Crystallographic Statistics for Data Collected from
Crystals of Native and Selenomethionine-Labeled XPD
Data Collection
Refined
Structure SeMet Peak SeMet Remote
l (A˚) 1.06 0.9787 anom.
pairs unmerged
0.9749 anom.
pairs unmerged
Resolution (A˚) 28  2.25 30  2.7 30  2.7
Last shell (A˚) 2.322.25 2.82.7 2.82.7
Spacegroup P21212 P21212
Cell (A˚) A = 95.7,
b = 100.3,
c = 62.5
a = 94.5,
b = 98.6,
c = 63.1
Unique refl’s 29129(2891) 31109(3103) 31244(3214)
Average
redundancy
6.2(3.9) 4.3(4.2) 8.6(8.5)
I/s 26.3(3.0) 23.0(2.8) 26.1(2.7)
Complete (%) 99.4(97.4) 99.5(96.5) 99.9(100.0)
Rmerge (%) 5.6(42.9) 4.5(52.0) 6.0(84.5)
Seleniums found 11 of 13
Refinement
R % 23.2 (28.7)
Rfree % 27.6 (32.9)
rmsd bonds (A˚)/
angles ()
0.010/1.197
Ramach’n
favored (%)
96
PDB accession
code
2VL7
The numbers in parentheses refer to the last shell.Figure 1. Structure of XPD
(A) Comparison of the domain organization of human and S. tokodaii XPD. Motor domain 1 is shown in cyan, motor domain 2 in salmon, the Arch domain in wheat
and the FeS domain in green. The positions of the canonical motifs are shown by colored bars, and the conserved sequences of these motifs are indicated. The
C-terminal region of human XPD that interacts with the p44 protein is shown as a gray box, and is not present in the archaeal XPD.
(B) Overview of the structure of XPD. Domains are colored as in 1A. The Arch domain (top of structure) arises as an insert into motor domain 1. The boundaries of
the FeS cluster binding domain, which is not visible in the electron density map, are indicated by green spheres. The canonical motifs defined in (A) are indicated
with the same color scheme and labeled. The phosphate ion in the ATP binding site is shown space-filled.
(C) S. tokodaii XPD is shown in the same orientation and color scheme as in (B). The DNA species shown as a red cartoon is taken from the cocrystal structure of
the 30 to 50 helicase Hel308 (PDB code 2p6r). The position of the DNA arises as a consequence from an overlay of the motor domains of the two enzymes without
any further modeling.
(D) GRASP representation of the electrostatic surface of XPD shown in the same orientation as (B) (left) and with a rotation of 90 (right). The narrow channel
formed between the Arch domain and motor domain 1 is lined with basic residues, and could accommodate ssDNA but not duplex DNA.
(E) Cartoon showing the likely path of DNA through the XPD helicase. Duplex DNA entering from the right is broken on the FeS domain, threading through the cleft
between the Arch domain and motor domain 1, engaging with the conserved helicase motifs Ia, Ib, IV, V, Va, and VII. The orphaned (30) strand of the duplex may
form interactions with the basic surface on the outside of the motor domain, shown in the right panel of 1D.Cell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc. 803
b sheet and four a-helices. There is no convincing match in the
protein databank (PDB) for the fold of the Arch domain, suggest-
ing this region represents a novel fold. The Arch domain is an
insertion into a loop of motor domain 1, sitting above the central
cleft between the two motor domains and making contact with
both. The Arch domain sequence is not highly conserved in
XPD family members, and is 60% larger in the eukaryotic
XPDs. This may provide further interaction surfaces with compo-
nents of TFIIH, including the CAK complex, which anchors to the
TFIIH core via an interaction with XPD (Chen et al., 2003).
The FeS domain (residues 84–141) is also an insertion in motor
domain 1. This small domain is disordered in our structure and its
boundaries are shown by green spheres in Figure 1B. The FeS
domain occupies a position above motor domain 1, equivalent
to the b-hairpin loop in the helicase UvrB (Theis et al., 1999)
(Figure S2B). UvrB is not, overall, a close structural match for
XPD (Rudolf et al., 2006), but carries out the analogous NER
step in bacteria. This predicted position would match the loops
seen in other helicases that have been termed the ‘‘plowshare,’’
and which function to separate the two strands of the DNA
duplex as single-stranded DNA is drawn across the top of the
motor domains.
The XPD structure is the first of an SF2 helicase with a 50 to 30
polarity, and helps explain the factors important for the determi-
nation of translocation polarity in helicases. As for the NS3
helicase, the motor domains of the 30 to 50 SF2 helicase Hel308
can be overlaid with those of XPD. This modeling positions the
ssDNA strand of the DNA substrate co-crystallized with Hel308
(Buttner et al., 2007) across the top of the XPD motor domains
(Figure 1C). The duplex portion of the Hel308 DNA substrate
(not shown) is on the left of XPD motor domain 2. Given that
XPD has the opposite polarity to Hel308, the duplex DNA is
predicted to be unwound on the opposite side of XPD, at domain
1. This is consistent with the proposed role for the FeS cluster do-
main in the physical separation of the DNA duplex strands (Pugh
et al., 2008; Rudolf et al., 2006). ssDNA would then pass across
the tops of domains 1 and 2 with the same polarity as the DNA
strand labeled in Figure 1C. The Arch domain bends over the
top of domain 1, forming a channel that could accommodate
single-stranded but not duplex DNA. The electrostatic surface
of the XPD protein shows a highly basic surface lining the narrow
channel formed between the Arch domain and domain 1
(Figure 1D). In addition, there is a basic surface on the back of
domain 1 that may interact with the orphaned 30 ssDNA strand.
By analogy with other DNA helicase structures, we propose
that the Arch domain and Fe-S loop collaborate to break the
DNA duplex and channel the 50 ssDNA end across the top of
the two motor domains, where it makes contact with the DNA
binding motifs on the motor domains (Figure 1E). This is sup-
ported by recent biochemical experiments that place the FeS do-
main near the junction of ssDNA and dsDNA (Pugh et al., 2008).
XP-Causing Mutations
XP-causing mutations tend to cluster in the helicase motifs, and
the residues whose mutation in human XPD gives rise to xero-
derma pigmentosum are all conserved in archaeal XPD
(Figure 2A, Figure S1). These observations support the theory
that XP is caused by mutations that inactivate the helicase with-804 Cell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc.out disrupting the structure, by targeting conserved catalytic or
DNA and ATP binding residues. These mutations are mapped
onto the XPD structure in Figures 2B and 2C. The likely path of
ssDNA is shown using the 8 deoxyuridine (8 dU) strand from
the crystal structure of the NS3 helicase (Kim et al., 1998). This
nucleic acid sequence has been placed without modeling, based
solely on the structural overlay between the motor domains of
XPD and NS3 (Figure S2A). Five of the residues targeted by
XP-causing mutations: (S. tokadaii residues with human muta-
tions in parenthesis) R365 (R511Q), S393 (S541R), Y394
(Y542C), D519 (D681N), and R521 (R683Q/W) cluster on the
top surface of domain 2 adjacent to the predicted route of the
ssDNA (Figures 2B and 2C). R683 is mutated in 75% of all known
XP-D mutations (Taylor et al., 1997). A sixth residue, T60 (T76A),
is in a suitable position to engage with the ssDNA at the top of
domain 1. Of the remaining residues, D182 (D234N, not shown
for clarity) targets the Walker B motif involved in ATP hydrolysis
while R437 (R601L/W) is not visible in the structure but is part of
motif V and predicted to lie close to the cluster of residues inter-
acting with ssDNA in domain 2.
XP/CS-Causing Mutations
The combination of XP and CS phenotypes is associated with
rare mutations in XPD, XPB and XPG (Dupuy and Lafforet,
1978). Patients suffer a combination of a classical XP phenotype
along with the severe neurological and developmental abnormal-
ities of CS (Lehmann, 2003). Four XPD mutations that give rise to
XP/CS are known: G47R, G602D, R666W, and G675R (Theron
et al., 2005) (Figure 2A). In structural terms, the observation
that three of the known XP/CS mutations target glycine residues
is provocative, given the unique role of glycine in providing con-
formational flexibility in a polypeptide chain. Studies of cells from
a XP/CS patient (van Hoffen et al., 1999) revealed decreased
TFIIH levels and an inability to remove UV damage from DNA
coupled with an increased level of incision of undamaged
DNA. This was recently confirmed in a mouse model of XP/CS
harbouring the XPD G602D mutation (Andressoo et al., 2006).
The combined XP and CS phenotypes suggest that these muta-
tions must have some effect on TFIIH structure and stability, giv-
ing rise to transcriptional defects that are distinct from those
generated by TTD mutations. In the structure, A438 (G602D)
lies next to the XP-targeted residue R437 (R601L/W) on a mobile
region of motif V, which is implicated in both ATP and ssDNA
binding. G38 (G47R) and R507 (R666W) are positioned close to
the ATP binding site in the interface between motor domains 1
and 2. Mutations in this region may interfere with the coupling
of ATP hydrolysis to DNA translocation. V513 (G675R) sits near
the bottom of domain 2, well away from the ssDNA and ATP
binding sites and close to a cluster of residues known to be
involved in the interaction with the p44 protein.
TTD-Causing Mutations
In marked contrast to the situation for XP mutations, only two out
of twelve residues mutated in TTD are conserved in archaeal
XPD (Figures 3A and S1). We showed previously that R112,
which is conserved as a lysine or arginine in archaeal XPDs, is
important for the stability of the FeS cluster binding domain, sug-
gesting that this mutation may destabilize XPD to some extent
Figure 2. Mutations of XPD Giving Rise to XP and XP/CS
(A) Schematic showing the domain structure and canonical motifs of S. tokodaii XPD. Domain boundaries are colored as in Figure 1A, and canonical motifs
indicated with black bars. The positions of residues targeted by mutation in XP and XP/CS are indicated, with the S. tokodaii residue and numbering in black
and the equivalent human residue numbering indicated immediately below in blue (XP) or orange (XP/CS).
(B) Structure of S. tokodaii XPD, colored as in Figure 1B, with the 8-mer dU oligonucleotide derived from the co-crystal structure of the NS3 helicase shown in red
(see also Figure S2). Residues mutated in XP and present in theS. tokodaii crystal structure are shown as space-filled sphere models, colored by element (carbon,
yellow; nitrogen, blue; oxygen, red). Residues R437 and A438 constitute part of the loop formed by motif V that is not observed in the crystal structure. Residue
D182, in motif II (the Walker B box) is omitted for clarity.
(C) Details as for (B), with the structure rotated vertically forward by 90. The Arch domain is omitted for clarity. The cluster of residues at the top of domain 2 close
to the expected position of the ssDNA is apparent.(Rudolf et al., 2006). G428 (R592P) and Y430 (A594P) sit on the
surface of the protein at the bottom of domain 2, well away
from the catalytic site of the enzyme (Figure 3C). The mutation
G595R in S. cerevisiae Rad3 (corresponding to G593R in human
XPD) maps to the same area of the protein and reduces the
Rad3-mediated inhibition of short sequence recombination
(Lee et al., 2000). Similarly, residues E454 (R616P) and D511
(D673G) group in the same area of the XPD protein surface
(Figure 3C). This cluster of mutations is in close proximity to
the eukaryotic XPD p44 interaction domain at the C terminus
of the protein, and it has been shown that the R616P/W mutants
fail to interact with p44 in vitro (Dubaele et al., 2003). These mu-
tations are thus likely to exert their phenotype by destabilizing
the interaction with p44 rather than destabilizing XPD directly.
Other TTD-causing mutations are likely to result in the direct
destabilization of the XPD structure. For example, I496
(R658H/C) forms part of the interface between the two motor do-
mains while T501 (C663R), points into the core of domain 2. Both
these mutations are likely to directly reduce the stability of
human XPD (and therefore TFIIH). It is particularly interesting to
note that TTD patients carrying the R658C mutation experienced
episodes of hair loss during bouts of pneumonia due to elevated
body temperature—a classic temperature-sensitive phenotype
that indicates decreased XPD and TFIIH stability (Vermeulen
et al., 2001). Finally, residue A206 (corresponding to TTD muta-
tion C259Y) points into the center of the helical bundle of the
Arch domain (Figure 3D) where it packs closely with other resi-
dues constituting the core of this domain. A bulky tyrosine resi-
due at this position in the human enzyme would be predicted
to destabilize the Arch domain. Mutation of the equivalent
residue in S. acidocaldarius XPD, A204Y, resulted in an active
enzyme that was temperature sensitive (Figures 3E and 4), con-
sistent with the theory that the C259Y mutation in TTD patients
destabilizes the XPD protein structure directly, in turn destabiliz-
ing the TFIIH complex.
Biochemical Analyses of XPD Mutations
The structure of XPD has allowed predictions to be made con-
cerning the molecular basis for many of the mutations found in
human XPD. To test the predictions, we studied the in vitroCell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc. 805
Figure 3. Mutations of XPD Giving Rise to TTD
(A) Schematic showing the domain structure and canonical motifs of S. tokodaii XPD. The positions of residues targeted by mutations causing TTD in human are
indicated. S. tokodaii residues and numbering are in black and the equivalent human residue numbering indicated immediately below in red.
(B) Structure of S. tokodaii XPD colored as in Figure 1. The residues targeted by TTD-causing mutations are represented in space-filled and labeled sphere
models as in Figure 2B. Residue K84 is on the boundary of the FeS domain and is not visible in the crystal structure. The position of the C terminus in the archaeal
XPD protein is also indicated.
(C) XPD structure with surface representation. The model is colored as in 3B and rotated 90 with respect to 3B to emphasize the bottom of domain 2. TTD mu-
tations mapping to the bottom surface of motor domain 2 are colored blue and labeled. In eukaryotic XPD, these residues together with the C-terminal extension
probably form an interaction surface with the p44 protein.
(D) Zoomed-in view of the boxed region of the Arch domain in Figure 3B. Residue A206 and surrounding residues are shown as space-filled molecular represen-
tations, with A206 in purple and other residues colored according to their atom type. The TTD mutation introducing a tyrosine at this position (C259Y) is likely to
cause significant disruption to the core of the Arch domain.
(E) Plot showing the temperature stability of the wild-type and A204Y mutant XPD enzymes from S. acidocaldarius (equivalent to S. tokodaii A206Y and human
C259Y). The helicase activity of the A204Y mutant is similar to that of the wild-type protein, but the mutant enzyme was inactivated on heating for 20 min at the
temperatures indicated before assaying for helicase activity. This confirms the predicted destabilizing effect of the C259Y mutation. Data points are means of
triplicate experiments and standard errors are shown.806 Cell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc.
biochemical properties of a selection of mutants generated in the
XPD protein from S. acidocaldarius. These mutants were ex-
pressed and purified in E. coli (Figure S3) and tested for ATPase
and helicase activities, and in some cases for ssDNA binding
affinity. This results in three numbering systems corresponding
to H. sapiens, S. tokodaii, and S. acidocaldarius, which can be
cross-referenced in Figure 4D; here we will indicate the mutation
made in S. acidocaldarius with the equivalent human mutation in
parenthesis. Three XP-causing mutations, R373Q (R511Q),
R531Q and R531W (R683Q/W) were generated and studied.
These mutants purified as for the wild-type enzyme and were
thermostable, suggesting that they caused no significant struc-
tural perturbation. All three mutants were active ssDNA-depen-
dent ATPases, with ATPase activities of approximately 50%
of the wild-type level for R373Q and R531W, and 170%
for R531Q. All three mutations resulted in weaker ssDNA binding
affinity, most pronounced in the R531W mutant, and were not
active as helicases. Taken together, these observations are con-
sistent with a role for these residues in helicase activity via inter-
actions with the translocating ssDNA, as suggested from the
structural analysis and consistent with the XP phenotype in hu-
mans. The elevated ATPase activity seen for R531Q may reflect
an uncoupling of ATP hydrolysis and DNA translocation as ob-
served previously for the XPD and PcrA helicases (Rudolf
et al., 2006; Soultanas et al., 2000). Two TTD-causing mutations
were also mimicked: A204Y which gives rise to an active but less
stable enzyme as discussed previously, and D521G (D673G).
The latter mutation causes no significant change in the ATPase,
helicase or DNA binding parameters compared to the wild-type
enzyme, as expected for a mutation that is thought to destabilize
the interaction of XPD with p44 (Dubaele et al., 2003).
Two XP/CS mutants, G447D (G602D) and C523R (G675R),
were expressed and characterized. Both were thermostable,
suggesting no serious destabilization of the protein. Both muta-
tions resulted in a severe decrease in the ssDNA-dependent
ATPase activity of XPD, and an abrogation of the helicase activ-
ity. The G447D (G602D) mutation targets helicase motif V, which
is mobile in the structure and spans the ATP binding and ssDNA
binding sites, so a significant decrease in ssDNA stimulated ATP
hydrolysis is clearly plausible. The dramatic consequences of the
C523R (G675R) mutation are less readily explainable. The
G675R mutant in eukaryotic XPD abolishes the interaction with
p44 in vitro (Dubaele et al., 2003), consistent with its position
near the bottom of domain 2. Unlike the TTD mutations in this
area, the G447D mutation in archaeal XPD abolishes the helicase
activity, which must be a consequence of a direct effect on catal-
ysis. Thus it seems most likely that this mutation in human XPD
has two consequences: a reduced helicase activity, possibly
via effects on the ATP-driven conformational cycling that is
essential for the helicase activity, and a destabilization of TFIIH.
DISCUSSION
Helicase Polarity and theRole of the FeSCluster Domain
The XPD structure is the first of a SF2 helicase with a 50 to 30 po-
larity, or SF2B according to the recently suggested nomencla-
ture (Singleton et al., 2007). The overall structure, with two
canonical motor domains and two unique accessory domains,conforms well to the paradigm established from structural stud-
ies of the NS3, PcrA, UvrD, Hel308 and other helicases. Although
DNA is not present in the structure, the positions of the Arch and
FeS domains argue strongly that ssDNA is bound in the same ori-
entation as in 30 to 50 polarity enzymes and that the enzyme sim-
ply translocates in the opposite direction. The same argument
has been put forward for RecD, the 50 to 30 SF1 helicase subunit
of bacterial RecBCD (Singleton et al., 2004). This orientation
matches that proposed by Spies and co-workers, based on
quenching of fluorescent DNA by the FeS domain in XPD from
Ferroplasma acidarmanus (Pugh et al., 2008).
The discovery of an essential FeS cluster-binding domain in
the XPD helicase prompted speculation as to its role. On the
one hand, FeS clusters are typically found in enzymes in a re-
dox-active form where they play a role in electron transport.
This raised the possibility that these helicases use the FeS clus-
ter to detect oxidative stress, or even to detect DNA damage
directly, as has been proposed for other FeS-containing DNA
repair proteins (Boal et al., 2005). XPD is related to three other
eukaryotic helicases, FancJ, RTel, and Chl1, all of which have
at least three cysteine residues required as FeS cluster ligands.
The observation that the FeS domain is found in a variety of hel-
icases with different functions suggests strongly that the role of
the cluster is not to detect specific forms of DNA damage, but
rather to function as a generic component of the helicase. This
supports the theory that the FeS cluster in these helicases is
a structural feature that stabilizes a small domain that physically
separates the DNA duplex strands.
A structural role for the FeS domain in XPD-family helicases is
also supported by bioinformatic analysis of the bacterial DinG
helicase, the closest bacterial homolog of XPD (Figure S4). On
the one hand, many DinG orthologs are predicted to have an
FeS domain in an equivalent position to XPD (Rudolf et al.,
2006), and this has been confirmed biochemically for E. coli
DinG (Voloshin and Camerini-Otero, 2007). However, sequence
analysis shows that other DinG sequences, such as that of
Staphylococcus aureus (Uniprot accession number Q6GGV4),
have no cysteine residues in this region of the protein and there-
fore no possibility of liganding an FeS cluster. We have con-
firmed this prediction by overexpressing the S. aureus DinG
protein in E. coli—the purified protein is an active helicase and
contains no iron (A.-M.M., unpublished data). Consistent with
the hypothesis that the FeS cluster has a purely structural role,
these organisms appear to have evolved an alternative domain
structure that obviates the requirement for the cluster.
Toward a Molecular Understanding
of XPD Mutation Phenotypes
The complex spectrum of phenotypes arising from mutation of
the xpd gene in humans has been the source of much discussion
and debate. XP-causing mutations are the simplest to under-
stand, manifesting as NER-defective but transcription-normal
in eukaryotic systems. They have been predicted to exert their
effect by reducing the helicase activity of XPD without affecting
the structure of TFIIH. In contrast TTD mutations have been pre-
dicted to disrupt the structure or stability of TFIIH and thus to
exert effects on both transcription and NER (Lehmann, 2003).
Consistent with these ideas, TTD linked mutants of XPD resultCell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc. 807
Figure 4. Biochemical Characterization of Selected Mutations of XPD
(A) Plot of the ssDNA-stimulated ATPase activities of the indicated wild-type and mutant proteins of S. acidocaldarius XPD. Relative ATPase activities are shown
in 4D. Experiments were carried out in triplicate and means with standard errors are shown. Data were fitted by a linear fit. Rates expressed as a percentage of the
wild-type rate with standard errors are shown in (D).808 Cell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc.
in markedly lowered levels of TFIIH in cells, whereas XP linked
mutants generally do not (Botta et al., 2002; Dubaele et al.,
2003). However, eukaryotic XPD is only fully active when assem-
bled in the TFIIH complex, and is specifically stimulated by its in-
teraction with p44. It has therefore not been possible to disentan-
gle the mutations that target the helicase activity directly from
those which destabilize protein:protein interactions important
for activity. Thus, both XP and TTD linked mutations reduce
XPD helicase activity and consequently NER capacity (Nishiwaki
et al., 2004). However, XP patients are highly cancer-prone while
TTD patients are not. This discrepancy has been explained as
a consequence of the subtle interplay between NER and tran-
scriptional defects in TTD patients, with the suggestion that the
rapid cell death and early senescence caused by TTD is protec-
tive against cancer (Andressoo et al., 2006).
Since the archaeal XPD is fully functional in the absence of
protein partners, it is a useful model system in which to deconvo-
lute the role of mutations. A priori, one can make three predic-
tions: first, that mutations that affect protein:protein interactions
would in general target less highly conserved residues in the
archaeal enzyme and result in negligible phenotypes. Second,
mutations that destabilize the XPD protein structure directly,
rather than disrupt complex formation, are unlikely to be con-
served but should give a detectable phenotype. Finally, muta-
tions that inactivate the helicase activity while preserving the sta-
bility of TFIIH should target conserved residues in the archaeal
enzyme and reduce the archaeal helicase activity. As described
above, bioinformatic comparisons and biochemical assays of
mutant proteins confirm all three of these predictions.
Our data are in broad agreement with the work of Egly and co-
workers (Dubaele et al., 2003), who showed that TTD but not XP
mutations inhibit transcription in vitro by destabilization of the
TFIIH complex. These studies demonstrated that the S541R
and R601W mutations do not compromise binding to p44 in vitro,
consistent with our data. However, they did demonstrate a weak-
ening of the XPD-p44 interaction for the R683W mutant. Given the
clustering of these 3 residues, their distance from other residues
known to interact with p44 and the XP phenotype of the R683W
mutation, which has no transcriptional defect associated with it
(Dubaele et al., 2003), we assume that the primary role of R683
is catalytic, and that TFIIH stability in vivo is close to normal for
this mutant. Potentially, the introduction of a bulky tryptophan res-
idue at this position has a subtle effect on human XPD stability.
In humans, XP/CS mutations combine the segmental progeria
of CS with the elevated cancer risk of XP (Lehmann, 2001). The
two XP/CS mutations generated in archaeal XPD both reduce
the ssDNA-stimulated ATPase and therefore helicase activity
significantly without reducing the protein stability. In this respectthey resemble XP rather than CS mutations. This reinforces stud-
ies of reconstituted human TFIIH containing XPD with the G602D
and G675R XP/CS mutations, which were both NER-deficient
and active in basal transcription, in contrast to CS and TTD mu-
tations (Dubaele et al., 2003). The challenge remains to deter-
mine why these mutations cause CS as well as XP symptoms,
and how this relates to the as yet unexplained elevation in strand
breakage events observed in human XP/CS cells and the XP/CS
model mouse (Andressoo et al., 2006; Berneburg et al., 2000).
Mutations targetting human XPD thus give rise to a broad
spectrum of pathologies, but also to a range of severity of clinical
symptoms. For example, it is notable that the clinical severity of
the R683W mutation is classed as severe, while that of the
R683Q mutation is moderate (Botta et al., 2002). This correlates
with our observation that the former mutation has a more delete-
rious effect on ssDNA binding affinity than the latter (Figure 4D).
Levels of TFIIH are reduced in some XP patients by up to 50%
without any obvious transcriptional defect, suggesting that XP
mutations may also partially destabilize XPD or its protein inter-
actions. Some TTD mutations, such as R112H, give rise to more
moderate clinical symptoms than others, suggesting that differ-
ences in the degree of destabilization of XPD and/or TFIIH give
rise to different phenotypes, as might be expected. A number
of TTD and XP patients are compound heterozygotes with a com-
bination of different mutations in the two copies of the XPD gene
(Botta et al., 1998), complicating functional analysis. A patient
with two mutant XPD alleles, leading to the mutations R112H
and L485P at the amino acid level, showed symptoms of both
TTD and XP (Broughton et al., 2001). Furthermore, patients
with identical mutations in XPD can have quite different clinical
symptoms, emphasizing the complexity of the disorders that
can arise in humans (Fujimoto et al., 2005).
In conclusion, we have described the crystal structure of the
DNA repair XPD helicase, the first structure of an SF2 helicase
with 50 to 30 polarity. The structure suggests strongly that heli-
case polarity is determined by the direction of translocation
rather than the nucleic acid binding orientation. The FeS cluster
present in this helicase family can now be ascribed a structural
role, stabilizing a small duplex-breaking ‘‘plowshare’’ domain. Fi-
nally, the structure allows the many naturally-occurring human
mutations of XPD, and the three overlapping diseases that can
result, to begin to be understood at a molecular level.
EXPERIMENTAL PROCEDURES
Expression and Purification of XPD from Sulfolobus Tokodaii
For crystallization trials, the xpd gene from Sulfolobus tokodaii str. 7 (Kawara-
bayasi et al., 2001) (ST1307, uniprot entry Q971R4) was cloned into the(B) Plot of the anisotropy changes resulting from binding of the indicated wild-type and mutant XPD proteins from S. acidocaldarius to a 15 nucleotide oligonu-
cleotide tagged with a 50 fluorescein reporter molecule. Apparent dissociation constants are shown in 4D. Experiments were carried out in triplicate and means
with standard errors are shown. Data were fitted as described in the Experimental Procedures.
(C) Helicase activities of wild-type and mutant proteins of S. acidocaldarius XPD showing the time course of unwinding of a partial DNA duplex with a 25 nt 50
overhang. Parental and product species were quantified by phosphoimaging and helicase activity is summarized in 4D. Control lanes are: c1, boiled DNA;
c2, no ATP control; c3, no XPD control.
(D) Summary of the biochemical properties of the wild-type and mutant proteins of S. acidocaldarius XPD. Equivalent numbering for the human and S. tokodaii
XPD homologs are also indicated. Helicase activity is scored as ‘‘++’’ for near-wild-type levels and ‘‘’’ for completely inactive mutants. The A204Y mutant was
active but temperature-sensitive, as described in Figure 3E. nd, not determined.Cell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc. 809
pDEST14 vector using a modified Gateway cloning system (Seetharamappa
et al., 2007). The cloned gene contained a TEV protease cleavable N-terminal
6x histidine tag. After removal of the tag, the purified XPD had one extra glycine
at the N-terminus. The XPD protein was expressed in E. coli strain C43 (DE3).
The transformed E. coli cells were grown in one liter of LB medium containing
100 mg/ ml of ampicillin to an OD600 = 0.6 and induced with 0.4 mM IPTG over-
night at 25C. Histidine-tagged XPD was purified using the automated work-
flow of the Scottish Structural Proteomics Facility. This utilized two steps of
nickel affinity chromatography intervened by a TEV cleavage step to remove
the tag and followed by gel filtration chromatography in buffer containing
10 mM Tris (pH 7.5) and 150 mM NaCl, as described previously (Seethara-
mappa et al., 2007). The purified recombinant XPD protein was concentrated
to 10 mg ml1 and the protein identity was confirmed by mass spectrometry.
The selenomethionine variant of XPD was expressed using the methionine bio-
synthesis inhibition method (Guerrero et al., 2001) and purified as described for
the wild-type with the only exception that purification buffers contained 5 mM
2-mercaptomethanol.
Protein Purification, Site-Directed Mutagenesis, ATPase,
and Helicase Assays
For biochemical analyses of wild-type and mutant XPD variants, the XPD pro-
tein from S. acidocaldarius was utilized. The protein was expressed and puri-
fied as described previously (Rudolf et al., 2006). Site-directed mutant forms of
the protein were constructed using the Quikchange protocol (Stratagene), se-
quenced fully to ensure sequence integrity and purified as for the wild-type en-
zyme. The oligonucleotide sequences used to construct the mutants are avail-
able from the corresponding author on request. ATPase and helicase assays
were carried out as described previously (Rudolf et al., 2006).
Structural Biology
Initial crystallization conditions were obtained with sitting-drop vapor diffusion
using several 96-condition crystal screening kits at 20C with a protein con-
centration of 10 mg ml1. Crystals appeared within 4 days in condition 30
of the JMAC screen, a PEG-based screen developed in house (S.A.M.,
unpublished data) (15% PEG 8K, 0.2 M Na-K-Phosphate, 0.1 M Na-Acetate,
[pH 5.6]). Optimization of this condition yielded single crystals from hanging
drop experiments using a mixture of 1 ml of the protein (4 mg ml1) and 0.5 ml
of precipitant solution containing 15% PEG 8K, 0.15 M Na-K-Phosphate, 0.1
M Na-Acetate, (pH 5.6). The crystal used for refinement of the native structure
was soaked in a cryoprotecting solution containing 20% PEG 8K, 0.1 M Na-K-
Phosphate, 0.1 M Na-Acetate, (pH 5.6), 20% PEG 400, mounted in a loop and
then immediately cooled to 100 K. Diffraction data were collected at Diamond
beamline I03 in two passes. A high resolution pass to a resolution of 2.25A˚
was collected as a total of 200 images with 10 s exposures for 0.5 oscilla-
tions. A low resolution pass to a resolution of 3.3 A˚ was collected as 180 im-
ages with 2.5 s exposure for 1.0 oscillations. The data were indexed, inte-
grated and scaled using HKL2000 (Otwinowski and Minor, 1997). A data set
to 2.25 A˚ was recorded with the space group determined as P21212. To de-
termine the phases, Se-Met crystals were obtained with the precipitant
18% PEG 8K, 0.2 M Na-K-Phosphate, 0.1 M Na-Acetate, (pH 5.6) using mi-
croseeding. The SeMet crystal was prepared in the same manner as the na-
tive crystal for data collection. A two wavelength MAD data set (peak and high
energy remote) was collected at ESRF beamline BM14 to a resolution of 2.7 A˚.
The two SeMet data sets were indexed, integrated and scaled using XDS and
XSCALE (Kabsch, 1993). 11 out of 13 possible selenium sites were located by
SHELXC and SHELXD (Schneider and Sheldrick, 2002) giving initial phases
with a figure of merit of 0.275 to 3.2 A˚ The initial phases were extended to
2.7 A˚ with a figure of merit of 0.53 by SHELXE (Schneider and Sheldrick,
2002). The phases were transferred to the native data and extended to 2.25
A˚ using DM (Cowtan, 1994). A model with 278 residues was built by hand, in-
put to ARP/warp (Perrakis et al., 1999) and finished manually. The structure
was refined using REFMAC5 and manually rebuilt with XFIT (McRee, 1999)
and COOT (Emsley and Cowtan, 2004). Simulated annealings were performed
using CNS (Brunger et al., 1998) and analyzed by superposition using Sequoia
(Bruns et al., 1999). Validation was performed using the Molprobity server
(Davis et al., 2007).810 Cell 133, 801–812, May 30, 2008 ª2008 Elsevier Inc.DNA Binding Assays
The DNA binding affinity of XPD was determined at 20C using a Cary Eclipse
fluorimeter (Varian) with automatic polarizer (excitation, 490 nm; emission,
535 nm). The excitation pathlength was 10 nm, the emission pathlength
2 nm and excitation slitwidth 5 nm. For direct titration, 20 nM 50-fluorescein la-
beled 15-mer oligonucleotide (50-TCGGAGTACAGTGGG) was equilibrated in
150 ml anisotropy buffer (20 mM HEPES [pH 7.1], 100 mM NaCl, 1 mM DTT,
0.01% Triton X-100). Anisotropy and total fluorescence intensity were mea-
sured in parallel following each protein addition and the effects of dilution
were corrected. To minimise rotational effects on fluorescence intensity,
‘‘magic angle’’ conditions were used. Each protein titration was repeated in
triplicate. Data were fitted to the equation below using KaleidaGraph (Synergy
Software):
A =Amin +

ðD+E+KDÞ 

ðD+E+KDÞ2ð4DEÞ
1=2
ðAmax  AminÞ=ð2DÞ
where A, anisotropy; E, total protein concentration; D, total DNA concentra-
tion; Amin (minimum anisotropy), anisotropy of free DNA; Amax (maximum
anisotropy), anisotropy of the DNA-protein complex; KD, the dissociation con-
stant. A 1:1 interaction between protein and DNA was assumed.
ACCESSION NUMBERS
The PDB code for the XPD coordinates is 2VL7.
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Supplemental Data include four figures and can be found with this article online
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